Phase i trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Hamamoto, Koichi Fukino, Takahiko Tanigawa, Yoshiteru Sumiyoshi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background We investigated the safety, pharmacokinetics, tumor response, and immunological parameters of sorafenib plus interferon á-2a (IFN) in Japanese patients with advanced RCC. Patients and methods After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week. Results A total of 18 patients received at least one dose of sorafenib plus IFN. Five patients had dose-limiting toxicities (DLTs). The most common DLT was fatigue, experienced in four DLT patients. All 18 patients experienced at least one treatment-emergent adverse event (AE). The most common treatment-emergent AEs included fatigue, fever, platelets, leukocytes, hemoglobin, weight loss and anorexia. Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%. IFN had no relevant impact on the pharmacokinetics of sorafenib. Conclusions Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy. Continuous sorafenib 400 mg twice daily in combination with IFN 6 MIU three times a week is recommended in Japanese patients with advanced RCC.

Original languageEnglish
Pages (from-to)1046-1054
Number of pages9
JournalInvestigational New Drugs
Volume30
Issue number3
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Interferons
Fatigue
Pharmacokinetics
sorafenib
Anorexia
Weight Loss
Hemoglobins
Leukocytes
Fever
Therapeutics
Blood Platelets
Safety

Keywords

  • Interferon
  • Phase I
  • Renal cell carcinoma
  • Safety
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase i trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. / Niwakawa, Masashi; Hashine, Katsuyoshi; Yamaguchi, Raizo; Fujii, Hirofumi; Hamamoto, Yasuo; Fukino, Koichi; Tanigawa, Takahiko; Sumiyoshi, Yoshiteru.

In: Investigational New Drugs, Vol. 30, No. 3, 01.06.2012, p. 1046-1054.

Research output: Contribution to journalArticle

Niwakawa, Masashi ; Hashine, Katsuyoshi ; Yamaguchi, Raizo ; Fujii, Hirofumi ; Hamamoto, Yasuo ; Fukino, Koichi ; Tanigawa, Takahiko ; Sumiyoshi, Yoshiteru. / Phase i trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. In: Investigational New Drugs. 2012 ; Vol. 30, No. 3. pp. 1046-1054.
@article{7e9e7f30f59f4eaabb2d7d7bf88b27e5,
title = "Phase i trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma",
abstract = "Background We investigated the safety, pharmacokinetics, tumor response, and immunological parameters of sorafenib plus interferon {\'a}-2a (IFN) in Japanese patients with advanced RCC. Patients and methods After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week. Results A total of 18 patients received at least one dose of sorafenib plus IFN. Five patients had dose-limiting toxicities (DLTs). The most common DLT was fatigue, experienced in four DLT patients. All 18 patients experienced at least one treatment-emergent adverse event (AE). The most common treatment-emergent AEs included fatigue, fever, platelets, leukocytes, hemoglobin, weight loss and anorexia. Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8{\%}. IFN had no relevant impact on the pharmacokinetics of sorafenib. Conclusions Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy. Continuous sorafenib 400 mg twice daily in combination with IFN 6 MIU three times a week is recommended in Japanese patients with advanced RCC.",
keywords = "Interferon, Phase I, Renal cell carcinoma, Safety, Sorafenib",
author = "Masashi Niwakawa and Katsuyoshi Hashine and Raizo Yamaguchi and Hirofumi Fujii and Yasuo Hamamoto and Koichi Fukino and Takahiko Tanigawa and Yoshiteru Sumiyoshi",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s10637-010-9630-0",
language = "English",
volume = "30",
pages = "1046--1054",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase i trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

AU - Niwakawa, Masashi

AU - Hashine, Katsuyoshi

AU - Yamaguchi, Raizo

AU - Fujii, Hirofumi

AU - Hamamoto, Yasuo

AU - Fukino, Koichi

AU - Tanigawa, Takahiko

AU - Sumiyoshi, Yoshiteru

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background We investigated the safety, pharmacokinetics, tumor response, and immunological parameters of sorafenib plus interferon á-2a (IFN) in Japanese patients with advanced RCC. Patients and methods After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week. Results A total of 18 patients received at least one dose of sorafenib plus IFN. Five patients had dose-limiting toxicities (DLTs). The most common DLT was fatigue, experienced in four DLT patients. All 18 patients experienced at least one treatment-emergent adverse event (AE). The most common treatment-emergent AEs included fatigue, fever, platelets, leukocytes, hemoglobin, weight loss and anorexia. Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%. IFN had no relevant impact on the pharmacokinetics of sorafenib. Conclusions Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy. Continuous sorafenib 400 mg twice daily in combination with IFN 6 MIU three times a week is recommended in Japanese patients with advanced RCC.

AB - Background We investigated the safety, pharmacokinetics, tumor response, and immunological parameters of sorafenib plus interferon á-2a (IFN) in Japanese patients with advanced RCC. Patients and methods After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week. Results A total of 18 patients received at least one dose of sorafenib plus IFN. Five patients had dose-limiting toxicities (DLTs). The most common DLT was fatigue, experienced in four DLT patients. All 18 patients experienced at least one treatment-emergent adverse event (AE). The most common treatment-emergent AEs included fatigue, fever, platelets, leukocytes, hemoglobin, weight loss and anorexia. Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%. IFN had no relevant impact on the pharmacokinetics of sorafenib. Conclusions Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy. Continuous sorafenib 400 mg twice daily in combination with IFN 6 MIU three times a week is recommended in Japanese patients with advanced RCC.

KW - Interferon

KW - Phase I

KW - Renal cell carcinoma

KW - Safety

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84864365547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864365547&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9630-0

DO - 10.1007/s10637-010-9630-0

M3 - Article

VL - 30

SP - 1046

EP - 1054

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -